Healthcare Publications Sex Cord Gonadal Stromal Tumor Market

Market Research Future has added a report titled “Sex Cord Gonadal Stromal Tumor Market
Research Report – Forecast to 2023” to its offering. The report provides an in-depth
analysis of regional data and an accurate projection of the market size and share of the Top
10 market players across the globe.
Market Scenario
The sex cord-gonadal stromal tumor is a rare type of cancer derived from the stromal
component of the ovary and testis. This tumor comprises granulosa, thecal cells, and
fibrocytes. Sex cord-gonadal stromal tumors are mostly of seven types, namely, granulosa
cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, gynandroblastoma, Sex Cord
Tumor with Annular Tubules (SCTAT), and Sertoli Leydig cell tumor. In humans, this type of
tumor accounts for 8% of the ovarian cancers and around 5% of testicular cancers.
It is noted that the increasing cases of ovarian and testicular cancer, technological
advancements, and increasing healthcare expenditure are the key factors driving the sex
cord-gonadal stromal tumor market.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5912
Various other factors such as the growing awareness about the cord-gonadal stromal tumor,
unmet medical needs, enhancing regulatory framework, increasing government assistance,
and rising funding and reimbursement are continuously contributing to the growth of the
global sex cord-gonadal stromal tumor market.
Despite these drivers, there are some setbacks associated with the sex cord-gonadal
stromal tumor market. Strict FDA regulations, a huge capital investment with low-profit
margins, and poor healthcare system in low and middle-income countries may hinder the
growth of the sex cord-gonadal stromal tumor market to a considerable extent.
It is estimated that the sex cord-gonadal stromal tumor market is expected to grow at a
CAGR of 6.5% during the forecast period of 2017–2023.
Key Players
Some of the key players in the Global Sex Cord–Gonadal Stromal Tumor Market are Abbott,
Abcam plc, Affymetrix, Inc., Agilent Technologies, Inc., Beckman, Dickinson and Company
(BD), Bio SB Inc., BioCurex, BioModa, Inc., Bio-Rad Laboratories, Inc., Boston Scientific
Corporation, Cell Signaling Technology, Inc., Clarient, Inc., CooperSurgical Inc., Correlogic
Systems, Inc., Danaher Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Gen-
Probe, Inc., Hologic, Inc., Johnson & Johnson Services, Inc., Karl Storz GmbH & Co. Kg,
LiNA Medical USA, Merck Millipore, PerkinElmer, Inc., Qiagen, Radient Pharmaceuticals,
Thermo Fisher Scientific Inc., Veridex LLC, and others.
Segmentation
The Global Sex Cord-Gonadal Stromal Tumor Market is segmented on the basis of type,
diagnosis, treatment, and end-user.
On the basis of tumor type, the sex cord-gonadal stromal tumor market is classified as
granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, Sertoli Leydig cell
tumor, gynandroblastoma, and Sex Cord Tumor with Annular Tubules (SCTAT). The
granulosa cell tumor is further classified as functioning tumors and non-functioning tumors.
On the basis of diagnosis, the Sex Cord-Gonadal Stromal Tumor Market is classified as
microscopy immunohistochemistry, tumor marker, ultrasound, Magnetic Resonance Imaging
(MRI), and others. The tumor marker segment is further classified as inhibin-alpha,
calretinin, Melan-A, and others.
On the basis of treatment, the sex cord-gonadal stromal tumor market is classified as
chemotherapy, radiotherapy, surgery, and others. The surgery segment is further classified
as salpingo-oophorectomy, abdominal hysterectomy, Retroperitoneal Lymph Node
Dissection (RPLND), and radical inguinal orchiectomy. The sub-segment of salpingo-
oophorectomy includes unilateral salpingo-oophorectomy and bilateral salpingo-
oophorectomy.
On the basis of end-user, the sex cord-gonadal stromal tumor market is segmented into
hospitals and clinics, cancer research centers, research and academic institutes, and others.